

Client/Product: Milestone Scientific/STA
For Release: **Immediately**
Contact: Michael Ventriello
mventriello@lanmarkgroup.com

527 Industrial Way West
Eatontown, NJ 07724
732.389.4500 | fax 732.389.4998

NEWS RELEASE
www.lanmarkgroup.com



**MILESTONE SCIENTIFIC LAUNCHES FDA-CLEARED
SINGLE TOOTH ANESTHESIA (STA™) SYSTEM
DURING CHICAGO MIDWINTER MEETING**

***New Technology Offers Precise, Predictable and
the Immediate Onset of Anesthesia Injections***

Livingston, NJ – February 20, 2007 – Milestone Scientific, Inc. (OTCBB: MLSS), a world leader in computer controlled local anesthetic delivery, will officially unveil its highly anticipated *Single Tooth Anesthesia (STA™)* System during this year's Chicago Dental Society Midwinter Meeting. Milestone will be conducting demonstrations of the STA™ System at booth # 2206.

The FDA-cleared STA™ System is comprised of a computer-controlled drive unit and a single-use disposable handpiece/needle assembly. It provides newly-patented real-time visual and audible feedback and verbal announcements via Milestone Scientific's patented *CompuFlo™* with Dynamic Pressure Sensing (*DPS™*) technology, thus taking the guesswork out of the administration of anesthetic.

Specifically, the STA™ System enables the dental professional to precisely administer an intraligamentary injection to anesthetize a single tooth in only one to two minutes*, rather than administering a mandibular block that anesthetizes an entire quadrant. The STA Intraligamentary injection has an immediate onset, whereas the typical block injection can take 8 to 12 minutes before a dentist can start treatment. In addition, the STA intraligamentary injection last as long as a traditional infiltration or mandibular block. All of this is accomplished with a technology that has been clinically proven to provide a pain-free injection.

** Using 4% Articaine Hydrochloride 1:200,000 local anesthetic solution.*

Using the innovative *CompuFlo with DPS* technology, the *STA™* System informs the clinician of the exact location of the needle point between the tooth and bone to directly target the periodontal ligament in order to comfortably anesthetize a single tooth without causing collateral numbing of the cheek, lips and tongue or histological damage commonly associated with the traditional PDL injection.

Moreover, the *STA™* System has been programmed to measure the precise “exit pressure of an anesthetic as it is injected into tissues of varying density. It provides constant information so that the dental professional is in the optimal location during the entire injection.

Furthermore, unlike traditional syringe injections, the *STA™* System allows the dental professional to start working immediately after the injection is administered, resulting in definitive and uninterrupted treatment saving valuable chair time. It also allows work to be performed in multiple quadrants and in both arches with ease, precision and efficiency, thus allowing multiple procedures to be completed in a single office visit.

The *STA™* System incorporates Milestone’s CompuDent technology which was introduced in 1998 and marked the first major advancement in local anesthetic delivery since the syringe was invented more than 150 years ago. Milestone’s *STA™* System is well-positioned to make a significant and positive impact on the predictability and productivity of the dental practice while improving the overall patient experience, by eliminating collateral anesthesia with a pain-free injection.

Milestone received FDA 510(k) Pre-market Notification acceptance in August 2006 for the marketing and sale of the *STA™* System and has since entered into an exclusive United States and Canadian distribution agreement with Henry Schein, Inc. (Nasdaq:HSIC), the world’s largest provider of healthcare products and services to office-based practitioners in the combined North American and European markets. For more information on Milestone Scientific’s *STA™* System, please call 877-STA-IS4U, or log on to www.STAis4U.com.

About Milestone Scientific, Inc.

Headquartered in Livingston, New Jersey, Milestone Scientific is engaged in pioneering proprietary, highly innovative technological solutions for the medical and dental markets. Central to the Company's IP platform and product development strategy is its patented *CompuFlo*[™] technology for the improved and painless delivery of local anesthetic. Specifically, *CompuFlo* is a computer-controlled, pressure-sensitive infusion, perfusion, and aspiration technology, which provides real-time readouts of pressures, fluid densities and flow rates, enabling the advanced delivery of a wide array of pharmaceutical. The *Single Tooth Anesthesia (STA)*[™] computer-controlled local anesthesia delivery system, which uses this technology, provides dentists with audible and visual signals as to in-tissue pressure. Milestone's existing painless injection systems are currently sold in 25 countries. For more information on these and other innovative Milestone products, please visit the Company's website found at www.milesci.com.

Safe Harbor Statement: This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report on Form 10-KSB for the year ended December 31, 2006. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

For Milestone Scientific Investor Relations:

Contact Elite Financial Communications Group, LLC
Dodi Handy, President and CEO, or Daniel Conway, Chief Strategist
407-585-1080 or mlss@efcg.net